COSCIENS Biopharma, Inc. (CSCI.TO)
7.50
+0.26
(+3.59%)
CAD |
TSX |
Aug 25, 10:26
COSCIENS Biopharma Enterprise Value : 2.971M for Aug. 24, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 24, 2026 | 2.971M |
| August 21, 2026 | 3.035M |
| August 20, 2026 | 3.725M |
| August 19, 2026 | 3.714M |
| August 18, 2026 | 3.078M |
| August 17, 2026 | 3.651M |
| August 14, 2026 | 3.651M |
| August 13, 2026 | 3.630M |
| August 12, 2026 | 3.630M |
| August 11, 2026 | 3.375M |
| August 10, 2026 | 2.982M |
| August 07, 2026 | 2.770M |
| August 06, 2026 | 2.770M |
| August 05, 2026 | 2.791M |
| August 04, 2026 | 2.823M |
| July 31, 2026 | 2.823M |
| July 30, 2026 | 2.876M |
| July 29, 2026 | 3.672M |
| July 28, 2026 | 3.672M |
| July 27, 2026 | 3.460M |
| July 24, 2026 | 3.460M |
| July 23, 2026 | 3.513M |
| July 21, 2026 | 3.513M |
| July 20, 2026 | 3.300M |
| July 17, 2026 | 3.778M |
| Date | Value |
|---|---|
| July 16, 2026 | 3.778M |
| July 15, 2026 | 3.746M |
| July 14, 2026 | 4.298M |
| July 13, 2026 | 4.309M |
| July 10, 2026 | 3.884M |
| July 09, 2026 | 7.811M |
| July 08, 2026 | 9.021M |
| July 07, 2026 | 6.485M |
| July 06, 2026 | 6.972M |
| July 03, 2026 | 6.940M |
| July 02, 2026 | 6.399M |
| June 30, 2026 | 5.603M |
| June 29, 2026 | 5.391M |
| June 26, 2026 | 5.263M |
| June 25, 2026 | 5.327M |
| June 24, 2026 | 4.754M |
| June 23, 2026 | 5.327M |
| June 22, 2026 | 5.422M |
| June 19, 2026 | 5.422M |
| June 18, 2026 | 5.996M |
| June 17, 2026 | 6.155M |
| June 16, 2026 | 5.454M |
| June 15, 2026 | 5.868M |
| June 12, 2026 | 4.945M |
| June 11, 2026 | 4.818M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Spectral Medical, Inc. | 420.22M |
| Resverlogix Corp. | 142.86M |
| Theratechnologies, Inc. | -- |
| Restart Life Sciences Corp. | 3.313M |
| Defence Therapeutics Inc | 36.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.2796M |
| Revenue (Quarterly) | 4.351M |
| Total Expenses (Quarterly) | 4.631M |
| EPS Diluted (Quarterly) | -0.267 |
| Gross Profit Margin (Quarterly) | 55.27% |
| Profit Margin (Quarterly) | -6.43% |
| Earnings Yield | -82.71% |
| Normalized Earnings Yield | -87.23 |